You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Rucaparib camsylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for rucaparib camsylate and what is the scope of patent protection?

Rucaparib camsylate is the generic ingredient in one branded drug marketed by Zr Pharma and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rucaparib camsylate has two hundred and thirty-one patent family members in forty-two countries.

Two suppliers are listed for this compound.

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for rucaparib camsylate
Generic Entry Date for rucaparib camsylate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for rucaparib camsylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alliance for Clinical Trials in OncologyPhase 3
National Cancer Institute (NCI)Phase 3
Clovis Oncology, Inc.Phase 2

See all rucaparib camsylate clinical trials

Pharmacology for rucaparib camsylate

US Patents and Regulatory Information for rucaparib camsylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zr Pharma RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Zr Pharma RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Zr Pharma RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Zr Pharma RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Zr Pharma RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Zr Pharma RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for rucaparib camsylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Zr Pharma RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 ⤷  Try a Trial ⤷  Try a Trial
Zr Pharma RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 ⤷  Try a Trial ⤷  Try a Trial
Zr Pharma RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for rucaparib camsylate

Country Patent Number Title Estimated Expiration
Japan 2015131858 8−フルオロ−2−{4−[(メチルアミノ)メチル]フェニル}−1,3,4,5−テトラヒドロ−6H−アゼピノ[5,4,3−cd]インドール−6−オンの塩および多形体 (SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE) ⤷  Try a Trial
Singapore 182533 SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE ⤷  Try a Trial
New Zealand 547984 DNA damage repair inhibitors for treatment of cancer ⤷  Try a Trial
China 102935230 Use of RNAi inhibiting PARP activtiy for the manufacture of a medicament for the treatment of cancer ⤷  Try a Trial
Taiwan 201144316 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ⤷  Try a Trial
Russian Federation 2006121459 ИНГИБИТОРЫ РЕПАРАЦИИ ПОВРЕЖДЕНИЯ ДНК ДЛЯ ЛЕЧЕНИЯ РАКА ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for rucaparib camsylate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2534153 2018/043 Ireland ⤷  Try a Trial PRODUCT NAME: RUCAPARIB CAMSYLATE; REGISTRATION NO/DATE: EU/1/17/1250 20180524
1633724 S1500012 Hungary ⤷  Try a Trial PRODUCT NAME: OLAPARIB
1633724 213 50005-2015 Slovakia ⤷  Try a Trial PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218
2534153 48/2018 Austria ⤷  Try a Trial PRODUCT NAME: RUCAPARIBCAMSYLAT; REGISTRATION NO/DATE: EU/1/17/1250 (MITTEILUNG) 20180529
1633724 1590019-4 Sweden ⤷  Try a Trial PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218
1633724 PA2015016,C1633724 Lithuania ⤷  Try a Trial PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.